Treatment of Melanoma by Nano-conjugate-Delivered Wee1 siRNA (2021)
Sequence: RRRRRRRR–cRGD
| Experiment Id | EXP002405 |
|---|---|
| Paper | Treatment of Melanoma by Nano-conjugate-Delivered Wee1 siRNA |
| Peptide | R8–cRGD CPP |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | RRCPP nanoparticles (siRNA mass ratio 5:1) |
| Rna Concentration | 2 µg siRNA per well (in vitro) |
| Mixing Ratio | RRCPP:siRNA = 5:1 (w/w) |
| Formulation Format | polymeric nano-conjugate (RRCPP/siRNA) |
| Formulation Components | LMW PEI (1.8 kDa), cholesterol, PEG, R8–cRGD peptide |
| Size Nm | 110.00 |
| Zeta Mv | 45.00 |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | B16F10 melanoma cells |
| Animal Model | |
| Administration Route | cell culture transfection |
| Output Type | gene knockdown, apoptosis |
| Output Value | >60% Wee1 mRNA knockdown; ~33% apoptotic cells |
| Output Units | |
| Output Notes | Strong siRNA uptake by flow cytometry and confocal microscopy; functional Wee1 silencing induces apoptosis and G2/M arrest. |
| Toxicity Notes | Low cytotoxicity compared to PEI25K |
| Curation Notes |